Recent research has described the development of iPSC-derived NK cells with four integrated functional edits designed to dual-target MM by incorporating an NK cell-optimized BCMA-specific CAR and a high-affinity, non-cleavable CD16 (hnCD16) receptor, termed as iDuo-MM CAR-NK cells. The gene discussed is FCGR3A; the disease is Miyoshi myopathy.